Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-18
2006-07-18
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S444000, C514S464000, C514S342000, C514S277000, C514S678000, C514S679000, C549S078000, C549S058000, C549S444000, C549S060000, C546S280400, C546S340000, C568S308000, C568S325000
Reexamination Certificate
active
07078431
ABSTRACT:
It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.
REFERENCES:
patent: 3862176 (1975-01-01), Fauran et al.
patent: 4085135 (1978-04-01), Kyogoku et al.
patent: 4855438 (1989-08-01), Kaulen et al.
patent: 4904697 (1990-02-01), Sunkara et al.
patent: 5155250 (1992-10-01), Parker et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5380747 (1995-01-01), Medford et al.
patent: 5608095 (1997-03-01), Parker et al.
patent: 5744614 (1998-04-01), Merkle et al.
patent: 5750351 (1998-05-01), Medford et al.
patent: 5773209 (1998-06-01), Medford et al.
patent: 5773231 (1998-06-01), Medford et al.
patent: 5783596 (1998-07-01), Medford et al.
patent: 5792787 (1998-08-01), Medford et al.
patent: 5807884 (1998-09-01), Medford et al.
patent: 5808137 (1998-09-01), Bombardelli et al.
patent: 5811449 (1998-09-01), Medford et al.
patent: 5821260 (1998-10-01), Medford et al.
patent: 5846959 (1998-12-01), Medford et al.
patent: 5877203 (1999-03-01), Medford et al.
patent: 5951541 (1999-09-01), Simpson et al.
patent: 6046212 (2000-04-01), Zwaagstra et al.
patent: 6423740 (2002-07-01), Bombardelli et al.
patent: 6562851 (2003-05-01), Clark et al.
patent: 6566095 (2003-05-01), Markham et al.
patent: 6579882 (2003-06-01), Stewart et al.
patent: 6583139 (2003-06-01), Thorsett et al.
patent: 6596687 (2003-07-01), Lin et al.
patent: 6608069 (2003-08-01), Daluge et al.
patent: 6617352 (2003-09-01), Somers
patent: 6624196 (2003-09-01), Purchase et al.
patent: 0 307 762 (1989-03-01), None
patent: 2175634 (1973-10-01), None
patent: 1408754 (1975-10-01), None
patent: 63010720 (1988-01-01), None
patent: 4-217621 (1992-08-01), None
patent: 6-092950 (1994-04-01), None
patent: 6-116206 (1994-04-01), None
patent: 7-330814 (1995-12-01), None
patent: WO 95/15760 (1995-06-01), None
patent: WO 96/20936 (1996-07-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 98/23581 (1998-06-01), None
patent: WO 98/51289 (1998-11-01), None
patent: WO 99/0014 (1999-01-01), None
patent: WO 98/51662 (1999-11-01), None
patent: WO 00/47554 (2000-08-01), None
Abraham, W., et al., “Blockade of Late-phase Airway Responses and Airway Hyperresponsiveness in Allergic Sheep with a Small-molecule Peptide Inhibitor of VLA-4,”Am. J. Respir. Crit. Care Med., (1997), 156, 696-703.
Albertini, et al., “Increase in Serum Levels of Adhesion Glycoprpteins in NIDDM Effect of Intensive Insulin Treatment,”Diabetologia, (1996), 39, A240.
Bakhite, E., et al., “Synthesis and Application of Some New Oxazole Derivatives as Antimicrobial Agents,” J. Chem. Tech.Biotech., (1992), 55, 157-161.
Baraczka, K., et al., “A Study Of Increased Levels Of Soluble Vasular Cell Adhesion Molecule-1 (sVCAM-1) In The Cerebrospinal Fluid Of Patients With Multiple Sclerosis And systemic Lupus Erythematosus,”Acta. Neurol. Scand., (1999), 99, 95-99.
Belmont, et al., “Up-Regulation of Endothelial Cell Adhesion Molecules Characterizes Disease Activity in Systemic Lupus Erythematosus,”Arthritis & Rheumatism,,(1994), 37(3), 376-383.
Boratynska, M., et al., :Soluble cell adhesion molecules in chronic renal graft rejection,Pol. Arch. Med. Wewn, (1998), 100, 410-410.
Bousquet, et al., “Eosinophilic Inflammation in Asthma”N. Engl. J. Med., (1990), 323(15), .
Braunstahl, G.J., et al., “Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways,”J. Allergy Clin. Immunol., (2001), 107, 469-476.
Calliste et al., “Chalcones: Structural Requirements for Antioxidant, Estrogenic and Antiproliferative Activities,”Anticancer Research, (2001), 21, 3949-3956.
Cheng et al., “Broussochalcone A, a potent antioxidant and effective suppressor of inducible nitric oxide synthase in lipoplysaccharide-activated macrophages,”Biochemical Pharmacology, (2001), 61, 939-946.
Cosimi, et al., “In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts,”J. Immunol., (1990), 144(12), 4604-4612.
Dimmock, et al., “Bioactivities of Chalcones,”Current Medicinal Chemistry, (1999), 6, 1125-1149.
Dimmock et al., “Cytotoxic Activities of Mannich Bases of Chalcones and Related Compounds,”J. Med. Chem., (1998), 41, 7, 1014-1026.
Dinkova-Kostova, et al., “Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups,”Proc. Natl. Acad. Sci. U.S.A., (Mar. 13, 2001), 98(6), 3404-3409.
Elovaara, et al., “Adhesion Moleules in Multiple Sclerosis,”Arch. Neurol., (2000), 57, 546-551.
Enghofer, et al., “Vasular Cell Adhesion Molecule 1 Mediates Islet Lymphocyte Adhession in Diabetic Insulitlis in Mice,” Diabetologia, (1996), 39, A97.
Frigerio, S.,et al., “Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients, ”Neuroimmunol., (1998), 87, 88-93.
Furuzawa-Carballeda, et al., “Interleukin-8, interleukin-10, intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Expression Levels are Higher in Synovial Tissue for Patients with Rheumatoid Arthritis than in Osteoarthritis,”Scand. J. Immunol., (1999), 50,215-222.
Goeke, et al., “Elevation of Soluble VCAM-1 in the Serum of Patients with Inflammatory Bowel Disease,”Gastroenterology, (1994), 106, A689.
Goggins, et al., “Serum VCAM-1 reflects the grade of intestinal inflammation in patients with Crohn's disease,”Gastroenterology, (1995), 108, A825.
Göke, et al., “Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease,”J. Gasterokenterol., (1997), 32, 480-486.
Gordon, et al., “Adhesion Molecule Expression in Inflammatory Bowel Disease (IBD) Patients Treated with Natalizumab (Antegrentm), a Humanized Antibody to A2 Integrin”Gastroenterology, (2000), 118 (No. 4, Suppl 2), A344.
Gosset, P., et al., “Expression of E-Selection, ICAM-1 and VCAM-1 on Bronchial Biopsies from Allergic an Non-Allergic Patients,”Int. Arch. Allergy Immunol., (1995), 106, 69-77.
Groves, R.E., et al., “Vascular cell adhesion molecule-1: Expression in normal and diseased skin and regulation in vivo by interferon gamma,”J. Am. Acad. Dermatol., (1993), 29, 67-72.
Grünbaum et al., “Nucleophilic Attacks on Carbon-Carbon Double Bonds. Part X. Nucleophile-catalysedcis-transIsomerisation ofcis-4-Nitrochalcone and of Diethyl Maleate in 95% Ethanol,”J. Chem. Soc., (1996), Section B, 1133-1137.
Hacken, N.H., et al., “Vascular cell adhesion molecules in nocturnal asthma: a possible role for VCAM-1 in ongoing airway wall inflammation,”Clin. Exp. Allergy, (1998), 29, 1518-1525.
Hart, et al., “Coronary Endothelial Cell VCAM-1 Expression is Enhanced in the Diabetic Mouse Heart,”FASEB J., (1997), 11(3), A340.
Herencia, et al., “Synthesis and Anti-inflammatory activity of chalcone derivatives,”Synthesis and Anti-flammatory Activity of Chalcone Derivatives, Bioorganic & Medical Chemistry Letters, (1998), 8, 1169-1174.
Herencia et al., “Novel anti-inflammatory
Hoong Lee K.
Meng Charles Q.
Ni Liming
Sikorski James A.
Atherogenics, Inc.
King & Spalding LLP
Knowles, Esq. Sherry M.
Lambkin Deborah C.
LandOfFree
1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3605272